Cabiralizumab - Five Prime Therapeutics/Bristol-Myers Squibb

Drug Profile

Cabiralizumab - Five Prime Therapeutics/Bristol-Myers Squibb

Alternative Names: BMS-986227; Cabiralizumab; FPA-008; ONO-4687

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pigmented villonodular synovitis
  • Phase I Cancer; Solid tumours
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Nov 2017 Adverse event and efficacy data from a phase Ia/Ib trial in Solid tumours released by Bristol-Myers Squibb and Five Prime Therapeutics
  • 09 Nov 2017 Bristol-Myers Squibb plans a phase II trial of cabiralizumab in combination with nivolumab for Pancreatic cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA in December 2017 (NCT03336216)
  • 08 Aug 2017 Five Prime Therapeutics plans a pivotal trial for cabiralizumab in Pigmented villonodular synovitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top